NCT04776525

Sequential Neoadjuvant Chemotherapy in Soft Tissue Sarcoma

Sequential Neoadjuvant Ifosfamide and Doxorubicin in Localized High-grade Soft Tissue Sarcoma of Extremities and Trunk Wall

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 49 (estimated)
• Sponsor: Oslo University Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Nearly half of patients with high-grade, localized soft tissue sarcoma (STS) of extremities and trunk wall develop disease recurrence after local therapy. Adjuvant chemotherapy with ifosfamide and doxorubicin may improve long-term disease-free survival, but the benefit of adjuvant treatment is limited and predictive factors for treatment response are lacking. The aim of this study is to explore sequential treatment with ifosfamide and doxorubicin in a neoadjuvant setting and to investigate biomarkers predictive of treatment response.

Conditions

• Soft Tissue Sarcoma

Interventions

Type	Name	Description
DRUG	Ifosfamide	3 g/m2 each day for three days
DRUG	Doxorubicin	80 mg/m2 over four hours day 1

Timeline

• Start date: 2021-04-27
• Primary completion: 2026-09-01
• Completion: 2036-09-01
• First posted: 2021-03-01
• Last updated: 2025-08-14

Locations

2 sites across 1 country: Norway